Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | ALPL | P05186 | 11/20 | 0.58 |
| ▸ | MAPT | P10636 | 6/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28813265 | 0.88 | MAPK1 (0.54) | MAPK1ALPLMAPTRAB9APOLB | |
| SCHEMBL970232 | 0.81 | ALPL (0.57) | MAPK1ALPLMAPTRAB9AGAA | |
| SCHEMBL285996 | 0.80 | MAPK1 (0.67) | MAPK1ALPLMAPTRAB9APOLB | |
| SCHEMBL68056 | 0.80 | MAPK1 (1.00) | MAPK1ALPLMAPTRAB9APOLB | |
| Hydrochloric Acid SCHEMBL28348020 | 0.79 | ALPL (0.56) | MAPK1ALPLMAPTRAB9AGAA | |
| SCHEMBL30614240 | 0.78 | MAPK1 (0.96) | MAPK1ALPLMAPTRAB9APOLB | |
| SCHEMBL21630583 | 0.78 | MAPK1 (0.65) | MAPK1ALPLMAPTRAB9APOLB | |
| SCHEMBL20517628 | 0.78 | MAPK1 (0.65) | MAPK1ALPLMAPTRAB9APOLB | |
| SCHEMBL286531 | 0.78 | MAPK1 (0.65) | MAPK1ALPLMAPTRAB9APOLB | |
| SCHEMBL30107039 | 0.78 | MAPK1 (0.70) | MAPK1ALPLMAPTRAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103880749-B | A kind of chemical synthesis process of 3- methyl -5- pyrazole carboxylic acid methyl esters | 南通大学 | 2019-01-01 | — | — | CN | claimed |
| CN-103880749-A | Chemical synthesis method of methyl 3-methyl-5-pyrazolylformate | UNIV NANTONG | 2014-06-25 | — | — | CN | claimed |
| EP-4735433-A2 | SUBSTITUTED PYRIDAZINE COMPOUNDS AS INHIBITORS OF NLRP3 ACTIVITY AND THERAPEUTIC USES THEREOF | Viva Star Biosciences (US) Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260070924-A1 | INDAZOLE MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS INC (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4705308-A1 | EGFR INHIBITORS FOR TREATING DISEASE | Blossomhill Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4562015-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | Cedilla Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| EP-4536225-A1 | INDAZOLE MACROCYCLES AND THEIR USE | Blossomhill Therapeutics, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| EP-4526298-A1 | PYRAZOLE DERIVATIVES AS STING AGONISTS | F. Hoffmann-La Roche AG (CH) | 2025-03-26 | — | — | EP | disclosed |
| US-20250074913-A1 | PYRAZOLE DERIVATIVES AS STING AGONISTS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-06 | — | — | US | disclosed |
| CN-119325379-A | Indazole macrocyclic compounds and uses thereof | 荣山医药股份有限公司 | 2025-01-17 | — | — | CN | disclosed |
| WO-2025006681-A2 | SUBSTITUTED PYRIDAZINE COMPOUNDS AS INHIBITORS OF NLRP3 ACTIVITY AND THERAPEUTIC USES THEREOF | VIVA STAR BIOSCIENCES (US) INC. (US) | 2025-01-02 | — | — | WO | disclosed |
| US-20040058281-A1 | Image forming method using photothermographic material | FUJIFILM CORPORATION (JP) | 2004-03-25 | — | — | US | disclosed |
| CN-1432608-A | Aldehyde deodorant composition and aldehyde deodorant coating material | OTSUKA KAGAKU KK (JP) | 2003-07-30 | — | — | CN | disclosed |
| US-6524781-B2 | Mixture of photosensitive silve rhalide emulsion, organic silver compound and reducing agent; controlling odors | KONICA CORPORATION (JP) | 2003-02-25 | — | — | US | disclosed |
| CN-1387445-A | aldehyde deodorant composition | OSHIKA SHINKO CO (JP) | 2002-12-25 | — | — | CN | disclosed |
| CN-1378462-A | deodorant composition | OTSUKA KAGAKU KK (JP) | 2002-11-06 | — | — | CN | disclosed |
| US-20020012888-A1 | Photothermographic material | KONICA CORPORATION, A CORPORATION OF JAPAN (JP) | 2002-01-31 | — | — | US | disclosed |
| US-5859007-A | TREATMENT OF DIABETES, OBESITY | GLAXO WELLCOME INC. (US) | 1999-01-12 | — | — | US | disclosed |
| EP-0755384-A1 | CCK OR GASTRIN MODULATING 1,5 BENZODIAZEPINES DERIVATIVES | GLAXO WELLCOME INC. (US) | 1997-01-29 | — | — | EP | disclosed |
| WO-1995028391-A1 | CCK OR GASTRIN MODULATING 1,5 BENZODIAZEPINES DERIVATIVES | GLAXO WELLCOME INC. (US) | 1995-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070924-A1 | INDAZOLE MACROCYCLES AND THEIR USE | NR0B2, NR0B1, ESRRA | MAPK1 3437/4885ALPL 3097/4885MAPT 3932/4885 |
| US-20250074913-A1 | PYRAZOLE DERIVATIVES AS STING AGONISTS | STING1, CGAS, MAVS | MAPK1 1071/4885ALPL 4759/4885MAPT 4128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.